RegineRX Biopharmaceuticals (RGRX)!
Attention Traders!
We’ve discovered a new BioPharma pick that we believe could stage an absolutely massive rally over the next few weeks.
But before we begin…
It’s important that all members read this report in its entirety so you understand exactly why this company, stands head-and-shoulders above the competition.
This clinical stage BioPharma company is trading at just .65 pps, and just received a huge $2 Price Target from Rodman & Renshaw (click here to read).
But that’s not even the good news!
What is important to note, is on page 4 of the Rodman & Renshaw report, is that the company has no financial obligation for any clinical trials due to another company they have partnered with; that is responsible for all funding and clinical development for the company’s primary product!
This is absolutely HUGE for shareholders! Here’s why:
Our new pick is ‘off-the-hook’ so to speak, for the very thing that prevents an up-and-coming biopharma company from hitting the ‘big-time…’
…Clinical Trials and Development costs!
This is huge for potential investors, because company bares no financial risk for the product development process, but is poised for all the potential fruits of success, coming from ongoing development!
Because of this…
We Are Issuing An Immediate Alert On RegeneRX Biopharmaceuticals (RGRX)!
RGRX is a clinical stage drug development company focused on tissue protection, repair and regeneration. The company’s primary drug is RGN-259, a treatment for dry eye syndrome.
As mentioned above, Rodman and Renshaw just issued a $2 Target on RGRX.
At the current price of .64 cents a move to $2 would represent a gain of over 200 pct from current levels!
Due to the unique situation of another company being responsible for the entire cost of clinical trials and development of the company’s drug, we believe RGRX has incredible upside and significantly lower financial risk.
Because of this we are urging all members to begin your research right away and lets be ready for RGRX on Thursday!
Rodman & Renshaw Initiate Coverage of RGRX
On March 14th , RegeneRx Biopharmaceuticals, Inc. (RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that Rodman & Renshaw, a unit of H.C. Wainwright & Co., has initiated coverage of RegeneRx Biopharmaceuticals, Inc. The firm has issued a Buy rating with a 12-month price target of $2 per share. The report is authored by Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D., CFA and is available here: Click here to read
Could RGRX be in for a Breakout?
It certainly looks that way. RGRX has been steadily moving higher and higher after the recent coverage issued by Rodman & Renshaw with a 2-dollar target.
What’s most significant is the partnership RGRX has with ReGenTree that requires them to be responsible for all clinical trials and development costs, but still positions RGRX to benefit significantly from the development of RGN – 259.
This significantly limits the risk for RGRX, since the primary failure of BioPharma company’s is not having the funds necessary for clinical trials and development costs!
RGRX avoids this issue entirely, yet still positions themselves to profit from the results!
From a technical perspective 7-Day Average Direction Indicator is showing upward trends developing in the near term and the 20 DayMoving Average Hilo Channel shows price action for two consecutives bars trading completely above and outside of channel indicating a “buy”-signal.
Both the 20 Day and 50 Day Moving Average vs Price charts support a bullish outlook in the near and medium terms respectively, with the 50 Day Parabolic Time/Price signaling a “buy”-action.
We are urging all members to begin your research on RGRX immediately and keep a close eye on RGRX throughout the coming week!
Do Not Miss RGRX: An Undiscovered BioPharma Company That Appears Drastically Undervalued After Recent 2-Dollar Target!
Happy Trading,
Your Penny Pick Finders team.
